UK – NICE recommends Lilly’s migraine med Emgality

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Emgality as a preventative treatment for migraine in adults with episodic and chronic migraine.

Emgality (galcanezumab) is a once-monthly subcutaneous injection – it binds to the calcitonin gene-related peptide (CGRP), which is believed to play a role in migraine attacks.

The NICE recommendation is based on results from a number of clinical trials which investigated Emgality’s efficacy and safety, including the CONQUER, REGAIN, EVOLVE-1 and EVOLVE-2 trials.

The EVOLVE-1 and EVOLVE-2 trials, which involved over 1,700 patients who had migraines between four and 14 days a month, demonstrated that those who received Emgality had four or five fewer days with migraines per month…